Invasight is a Swiss-based early-clinical stage biotech start-up. Using our breakthrough technology, ACINDATM, we develop novel inhibitors against specific proteins, which causes cancer cell invasion. Invasight’s precise therapies will make a positive difference in the lives of patients with invasive cancers.